Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

Study finds key association between Kallikrein 6 and malignant tumors

One of the most common types of brain tumors in adults, glioblastoma multiforme, is one of the most devastating. Even with recent advances in surgery, radiation and chemotherapy, the aggressive and invasive tumors become resistant to treatment, and median survival of patients is only about 15 months. In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and the malignant tumors.

18 Jan 2013

ELTD1 biomarker may help diagnose glioma

Researchers using sophisticated genetic testing techniques have identified a promising new biomarker for diagnosis of glioma—the most common type of malignant brain tumor, reports the January issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

17 Jan 2013

DESI technique identifies cancer type, grade and tumor margins in brain surgery patients

A new tool that could allow for faster, more comprehensive testing of brain tissue during surgery successfully identified the cancer type, grade and tumor margins in five brain surgery patients, according to a Purdue University and Brigham and Women's Hospital study.

11 Jan 2013

Massage could ease distress of brain cancer

Massage therapy can significantly reduce distress levels in individuals with brain tumors, indicating its potential use to improve quality of life in this population, report US researchers.

13 Dec 2012

Combination of ketogenic diet and radiation therapy effectively treats malignant gliomas

A team of brain cancer researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has effectively treated brain tumor cells using a unique combination of diet and radiation therapy.

5 Dec 2012

Studies explore F-18-FLT PET utility in providing prognostic information for patients with gliomas

In the management of gliomas-or tumors that originate in the brain-precise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival.

4 Dec 2012

Combination of perifosine and temsirolimus shows promise against malignant glioma

Aeterna Zentaris Inc. today announced that perifosine, its oral AKT inhibitor, combined with temsirolimus ("TEM"), was well tolerated in an investigator driven Phase 1 clinical trial in recurrent or progressive malignant glioma ("MG").

20 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Scientists identify cell growth pathway that is unusually active in gliomas

Insights from a genetic condition that causes brain cancer are helping scientists better understand the most common type of brain tumor in children.

17 Nov 2012

Patient recruitment complete for immatics IMA901 Phase 3 trial for renal cell carcinoma

immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries in the US and Europe.

8 Nov 2012

‘Postcode lottery’ sheds light on low-grade glioma strategy

Survival of adult patients with low-grade gliomas is better if they are admitted to a hospital that favors early resection, rather than one that opts for biopsy and watchful waiting, shows a study in JAMA.

26 Oct 2012

Human Gene Therapy articles describe two novel anti-tumor therapies

Targeted T-cells can seek out and destroy tumor cells that carry specific antigen markers. Two novel anti-tumor therapies that take advantage of this T-cell response are described in articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

26 Oct 2012

Study explores effects of immunotherapy on malignant gliomas

In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different types of brain tissue, shedding light on why cancerous brain tumors are so difficult to treat.

28 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

Potassium-channel autoimmunity linked to chronic pain

A substantial proportion of patients with voltage-gated potassium channel-complex autoimmunity experience chronic idiopathic pain, although the specific antigenic complex associated with pain remains to be determined, conclude US scientists.

3 Sep 2012

New drug combines photothermia and chemotherapy to help fight cancer

Spanish researchers have developed on a nanometric scale a new drug that combines photothermia and chemotherapy to help fight cancer.

3 Sep 2012

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012